Active, not recruitingNCT04982393
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
Studying Primary hyperoxaluria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alnylam Pharmaceuticals
- Principal Investigator
- Medical DirectorAlnylam Pharmaceuticals
- Enrollment
- 207 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- Clinical Trial Site, Phoenix, Arizona, United States
- Clinical Trial Site, Washington D.C., District of Columbia, United States
- Clinical Trial Site, Boston, Massachusetts, United States
- Clinical Trial Site, Rochester, Minnesota, United States
- Clinical Trial Site, Cincinnati, Ohio, United States
- Clinical Trial Site, Pittsburgh, Pennsylvania, United States
- Clinical Trial Site, Dallas, Texas, United States
- Clinical Trial Site, Houston, Texas, United States
- Clinical Trial Site, Ghent, Belgium
- Clinical Trial Site, Liège, Belgium
- Clinical Trial Site, Hamilton, Ontario, Canada
- Clinical Trial Site, Toronto, Ontario, Canada
- Clinical Trial Site, Laurier, Quebec, Canada
- Clinical Trial Site, Bordeaux, France
- Clinical Trial Site, Lyon, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04982393 on ClinicalTrials.govOther trials for Primary hyperoxaluria
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06839235Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)Arbor Biotechnologies
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06892301Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)Guangzhou Women and Children's Medical Center
- RECRUITINGEARLY PHASE1NCT06511349Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)RenJi Hospital
- RECRUITINGNCT06225882Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.Hospices Civils de Lyon
- RECRUITINGPHASE2NCT04580420Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRDDicerna Pharmaceuticals, Inc., a Novo Nordisk company